Patents Assigned to Scandion Oncology A/S
  • Combination treatment of cancer
    Patent number: 11903927
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: February 20, 2024
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • Combination treatment of cancer
    Patent number: 11103481
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1
    Publication number: 20210251963
    Abstract: The present invention relates to treatment of diseases characterized by elevated expression and/or activity of SRPK1 with specific SRPK1 inhibitors and to methods for identifying subjects who may benefit from such treatment.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 19, 2021
    Applicant: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Jan Stenvang
  • 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
    Patent number: 10975079
    Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or propharmacons thereof for use as BCRP inhibitors, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant ?p greater than 0.23. For corresponding compounds, surprisingly a particularly high inhibitory activity against BCRP has been discovered which can be exploited for suppressing the multidrug resistance modulator BCRP, thus providing an improvement in efficacy of BCRP affected drugs. This has useful implications for cancer and HIV treatment.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: April 13, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Steffen Rump, Henning Weigt
  • 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances
    Patent number: 9790225
    Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula I or pharmaceutically acceptable salts or propharmacons thereof, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant ?p greater than 0.23. The present invention also concerns the method of its manufacture. For corresponding compounds, surprisingly a particularly high activity against viruses, in particular rhinoviruses and picornaviruses was determined. Furthermore, the compounds are tolerated very well. For these reasons the compounds are suitable for the treatment of viral infections and as drugs.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: October 17, 2017
    Assignee: Scandion Oncology A/S
    Inventors: Peter Wutzler, Michaela Schmidtke, Vadim Makarov